Please provide your email address to receive an email when new articles are posted on . In patients who underwent surgical bioprosthetic valve implantation or repair, early postoperative ...

Elderly patients with atrial fibrillation (AF) who are at high risk of bleeding may benefit from a low 15-mg dose of edoxaban, regardless of their frailty status, a subanalysis of the ELDERCARE-AF ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be ...

WASHINGTON, DC—In another negative result for a direct oral anticoagulant in the post-TAVI setting, edoxaban (Savaysa; Daiichi Sankyo) did not have an advantage over dual antiplatelet therapy (DAPT) ...

LISBON, Portugal—Use of uninterrupted edoxaban (Savaysa; Daiichi Sankyo) during catheter ablation for A-fib is associated with rates of thromboembolic and bleeding events that are low and comparable ...

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved edoxaban (Savaysa, Daiichi-Sankyo), a factor Xa inhibitor, for the prevention of stroke and non–central-nervous-system (CNS) ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...

Boston, MA – According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious ...

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final matrix Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - ...

A direct oral anticoagulant (DOAC) passed a test of efficacy but tripped up over bleeding rates when used for patients who came out of successful transcatheter aortic valve replacement (TAVR) and ...

A new study compares edoxaban anticoagulant with the standard of care in large randomized clinical trial. The anticoagulant edoxaban may be just as effective as warfarin for preventing heart attack or ...

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final matrix Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - ...